Codexis Announces Enhanced Strategic Focus and Extends Projected Cash Runway to Mid-2026
Enzyme-catalyzed oligonucleotide synthesis for RNAi therapeutics – review the most recent technical update presented at the TIDES Europe annual meeting in November 2023
Deal creates strategic collaboration to enable more efficient RNA therapeutic development, providing a path to GMP-grade Codexis enzymesLearn More
At Codexis, we strive to innovate sustainable processes and products, and discover and develop effective therapeutics – all to create a brighter future.
These goals are grand but not beyond reach. Together with our business partners and loyal customers, we can make them a reality.
Held on March 28, 2023, scientists from Codexis and Tune Therapeutics presented how engineered enzymes can overcome common challenges with capping efficiency and dsRNA impurities in IVT manufacturing of mRNA required for vaccines and cell/gene therapeutics.Watch now